Skip to main content
MedPathMedPath Home
Clinical Trials/RPCEC00000369
RPCEC00000369
Not yet recruiting
Phase 1

Safety and efficacy study of the monoclonal antibody nimotuzumab in the treatment of severe patients with SARS-CoV-2 pneumonia. (COVID-19) - NIMO COVID-19

Center of Molecular Immunology (CIM)0 sites40 target enrollmentMay 21, 2021
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsCOVID-19SARS-CoV2Coronavirus InfectionsSARS VirusCoronaviridae InfectionsBetacoronavirusAcute DiseaseCritical Care

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
COVID-19
Sponsor
Center of Molecular Immunology (CIM)
Enrollment
40
Status
Not yet recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 21, 2021
End Date
August 31, 2021
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
Center of Molecular Immunology (CIM)

Eligibility Criteria

Inclusion Criteria

  • •1\.\- Any gender and skin color
  • •2\.\- Age equal to or greater than 19 years
  • •3\.\- Patients in a severe stage of COVID\-19 of the disease defined by any of the following conditions:
  • •\- Patients who have SpO2 \<94% or patients in need of oxygen therapy to maintain SO2\> 93% or
  • •\- Patients with a PaO2 / FiO2 ratio \<300 mm Hg or
  • •\- Patients with a respiratory rate\> 30 inspirations / min,
  • •\- Patients with infiltrate in more than 50% of both lung fields

Exclusion Criteria

  • •1\.\- Pregnant or lactating women.
  • •2\.\-Under 19 years.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Phase 1
imotuzumab cold kit for the immunodiagnosis of solid tumorsLung DiseasesTumors of head and neck, lung and gliomasHead and Neck NeoplasmsLung NeoplasmsGliomaRespiratory Tract NeoplasmsThoracic NeoplasmsRespiratory Tract DiseasesNeoplasms, NeuroepitheliaNeoplasms, Glandular and EpithelialNeoplasms, Germ Cell and EmbryonalNeoplasms, Nerve TissueNeuroectodermal Tumors
RPCEC00000290Center of Molecular Immunology (CIM)
Active, not recruiting
Phase 1
Safety, Tolerability and Efficacy of the Therapeutic Antibody Felzartamab in Rejection Late After Kidney Transplantatioate active or chronic active antibody-mediated rejectionTherapeutic area: Body processes [G] - Immune system processes [G12]
EUCTR2021-000545-40-DEMedical University of Vienna20
Active, not recruiting
Phase 1
Safety, Tolerability and Efficacy of the Therapeutic Antibody Felzartamab in Rejection Late After Kidney Transplantatioate active or chronic active antibody-mediated rejectionTherapeutic area: Body processes [G] - Immune system processes [G12]
EUCTR2021-000545-40-ATMedical University of Vienna22
Completed
Not Applicable
Study for effects of Haemophilus Influenzae type b conjugate vaccine in childreChildren Haemophilus Meningitis.Meningitis due to Haemophilus influenzae
IRCT201008084536N1Masoondarou Co.50
Active, not recruiting
Not Applicable
Trial aimed at evaluating the activity of the anti-ALK1 monoclonal antibody PF-03446962 in relapsed or refractory urothelial cancer (UC) failing first-line treatment.
EUCTR2011-005983-12-ITISTITUTO NAZIONALE PER LA CURA TUMORI